$469.25 Million in Sales Expected for Jazz Pharmaceuticals PLC (JAZZ) This Quarter
Analysts expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to report $469.25 million in sales for the current quarter, according to Zacks Investment Research. Nine analysts have made estimates for Jazz Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $464.60 million and the highest estimate coming in at $472.21 million. Jazz Pharmaceuticals reported sales of $394.39 million during the same quarter last year, which suggests a positive year-over-year growth rate of 19%. The company is scheduled to announce its next quarterly earnings report on Tuesday, August 14th.
On average, analysts expect that Jazz Pharmaceuticals will report full year sales of $1.90 billion for the current fiscal year, with estimates ranging from $1.88 billion to $1.92 billion. For the next fiscal year, analysts anticipate that the company will report sales of $2.17 billion per share, with estimates ranging from $2.07 billion to $2.26 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.73 by ($0.15). The company had revenue of $436.40 million for the quarter, compared to analysts’ expectations of $440.91 million. Jazz Pharmaceuticals had a return on equity of 23.78% and a net margin of 26.51%.
Jazz Pharmaceuticals opened at $169.00 on Friday, MarketBeat.com reports. The company has a current ratio of 3.00, a quick ratio of 2.88 and a debt-to-equity ratio of 0.55. The company has a market cap of $9.93 billion, a price-to-earnings ratio of 17.68, a P/E/G ratio of 0.85 and a beta of 0.97. Jazz Pharmaceuticals has a fifty-two week low of $128.58 and a fifty-two week high of $169.25.
In related news, SVP Karen J. Wilson sold 3,899 shares of the firm’s stock in a transaction on Tuesday, April 10th. The shares were sold at an average price of $155.00, for a total transaction of $604,345.00. Following the completion of the sale, the senior vice president now directly owns 19,517 shares of the company’s stock, valued at approximately $3,025,135. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Paul Treacy sold 594 shares of the firm’s stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $141.47, for a total transaction of $84,033.18. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 15,825 shares of company stock valued at $2,467,865. Company insiders own 4.30% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in JAZZ. Summit Trail Advisors LLC grew its holdings in Jazz Pharmaceuticals by 8,591.5% during the 1st quarter. Summit Trail Advisors LLC now owns 102,125 shares of the specialty pharmaceutical company’s stock valued at $102,000 after purchasing an additional 100,950 shares in the last quarter. US Bancorp DE grew its holdings in Jazz Pharmaceuticals by 49.5% during the 4th quarter. US Bancorp DE now owns 1,087 shares of the specialty pharmaceutical company’s stock valued at $147,000 after purchasing an additional 360 shares in the last quarter. We Are One Seven LLC acquired a new stake in Jazz Pharmaceuticals during the 4th quarter valued at $157,000. Financial Gravity Wealth Inc. acquired a new stake in Jazz Pharmaceuticals during the 1st quarter valued at $192,000. Finally, Brighton Jones LLC acquired a new stake in Jazz Pharmaceuticals during the 1st quarter valued at $205,000. 89.23% of the stock is owned by institutional investors and hedge funds.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.